Biotech AI: Pande leaves a16z, bets small with VZVC

Vijay Pande, after managing roughly $4 billion in biotech for a16z, decided to shift his strategy. He left the fund in 2023 to launch VZVC, a much leaner, AI-native venture. Instead of making dozens of investments, Pande aims for a smaller, yet more significant number.

His philosophy is simple: you don't need to make "30 bets a year" to find the next unicorn. VZVC will focus on specific projects where artificial intelligence can genuinely make a difference. This targeted approach allows him to be more selective and, potentially, more impactful. Isn't it counterintuitive to leave a giant to start over like this?

Yes, according to Pande, biology is finally shifting from a "discovery" science to an "engineering" one. It's no longer just about finding new molecules or processes. Now, we can design and build them with precision, much like in computer science. This paradigm shift is crucial for AI.

Artificial intelligence excels at design and optimization. It can help us construct tailor-made biological solutions. However, one bottleneck remains: clinical trials. They are still brutally expensive and time-consuming, a real choke point in the development process. No AI, for now, can completely eliminate that cost.

Pande is convinced that open, shared datasets are the real key to transforming medicine with AI. Data locked away in corporate silos helps no one; in fact, it slows down research. Sharing, on the other hand, is the engine of innovation, especially in a field as complex as healthcare.

Imagine an AI learning from billions of anonymous patient data points, available to all researchers. This would accelerate drug discovery and diagnoses like never before. The current model, with proprietary data, only hinders progress. Doesn't it take some guts to abandon the old way?